ClinicalTrials.Veeva
Menu

Find clinical trials for COVID-19 in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Infections
Coronavirus Infections
Human Influenza
Communicable Diseases
Post-Acute COVID-19 Syndrome
Pneumonia
Syndrome

COVID-19 trials near Paris, Île-de-France, FRA:

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

seek to enroll immunocompromised patients with Lower Tract parainfluenza infection.It also contains a sub-study to enroll patients with severe COVID...

Enrolling
COVID-19
Parainfluenza
Drug: DAS181 COVID-19
Drug: DAS181

Phase 3

Ansun Biopharma

Créteil, Ile-de-France, France and 66 other locations

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most oft-...

Enrolling
Coronavirus Disease (COVID-19)
Drug: Placebo
Drug: Molnupiravir

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Paris, Ile-de-France, France and 149 other locations

NEUROCOVID is a prospective multicenter study comparing the proportion of patients with SARS-CoV-2 viral RNA at the level of the olfactory clefts in...

Enrolling
Cognitive Disorder
SARS-CoV-2 Infection
Biological: Nasopharyngeal swab for RT-PCR SARS-CoV-2
Fondation Ophtalmologique Adolphe de Rothschild

Paris, France and 1 other location

One of the current health challenges in the face of the COVID-19 pandemic that started in Wuhan in 2019, and still responsible for ...

Enrolling
COVID-19
Other: Saliva sample collection
Other: Nasopharyngeal and nasal sample collection
Pasteur Institute
Pasteur Institute

Paris, France

Currently, there is no approved treatment for COVID-19 in France, either for the acute phase, nor for the late chronic phase. the i...

Enrolling
SARS-Cov-2 Induced Pulmonary Fibrosis
Drug: Nintedanib 150 MG [Ofev]
Other: Placebo

Phase 3

Assistance Publique - Hôpitaux de Paris

Paris, France

The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants...

Active, not recruiting
Sickle Cell Disease (SCD)
Drug: Crizanlizumab

Phase 2

Novartis
Novartis

Paris 15, France and 35 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Paris cedex 10, Paris, France and 246 other locations

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental...

Enrolling
Viral Lung Infection and Acute Respiratory Failure
Drug: Tozorakimab
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Créteil, France and 442 other locations

Globally, women accounted for more than half of people living with HIV (53%) in 2022. In France, 54% of new infections were heterosexual in 2022, 71%...

Enrolling
Vulnerable Population
Diagnostic Test: Rapid diagnostic orientation tests (TROD) HIV, Hepatitis, syphilis
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida

Paris, France and 1 other location

This is a French multicenter open label non-randomized Phase II trial evaluating the efficacy and tolerance of a combination of oral zanubrutinib and...

Not yet enrolling
Waldenstrom Macroglobulinemia
Drug: zanubrutinib + BGB-11417

Phase 2

French Innovative Leukemia Organisation

Paris, France and 36 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems